Literature DB >> 9489938

Sensitivity of the fear-inhibited light reflex to diazepam.

P Bitsios1, E Szabadi, C M Bradshaw.   

Abstract

We have shown previously that pupil diameter increases and the amplitude of the pupillary light reflex is reduced when subjects are under threat of an aversive event (electric shock), and that light reflex amplitude correlates negatively with subjective anxiety. We have suggested that the "fear-inhibited light reflex" paradigm could be used as a laboratory model of human anxiety. In the present study, we examined whether two doses (5 mg and 10 mg) of the anxiolytic drug diazepam would antagonize the effects of threat on the pupillary light reflex. Twelve healthy male volunteers participated in three weekly sessions, each associated with one of three treatments (diazepam 5 mg or 10 mg or placebo) in a double-blind, balanced, cross-over design. The light reflex was recorded during either the anticipation of a shock ("threat" blocks) or periods in which no shocks were anticipated ("safe" blocks). At the end of each "threat" or "safe" block, subjects rated their anxiety using visual analogue scales. Two-factor ANOVA (treatment x condition) showed that diazepam treatment antagonized the effect of threat on light reflex amplitude in a dose-dependent manner but it did not affect the threat-induced increase in pupil diameter. Diazepam had no effect on the pupillary light reflex in the "safe" condition. Diazepam also reduced subjective anxiety and alertness in the threat condition. These results show the sensitivity of the threat-induced reduction of light reflex amplitude to anxiolytic drugs, and provide further evidence for the utility of the fear-inhibited light reflex paradigm as a laboratory model of human anxiety.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9489938     DOI: 10.1007/s002130050489

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  8 in total

1.  Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine.

Authors:  Ruihua H Hou; Jessica Scaife; Clare Freeman; Rob W Langley; Elemer Szabadi; Chris M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

2.  Effect of dexmedetomidine, an alpha2-adrenoceptor agonist, on human pupillary reflexes during general anaesthesia.

Authors:  M D Larson; P O Talke
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

3.  Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers.

Authors:  Vassilis Koudas; Alexandra Nikolaou; Eugenia Hourdaki; Stella G Giakoumaki; Panos Roussos; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

4.  Arousal and the pupil: why diazepam-induced sedation is not accompanied by miosis.

Authors:  R H Hou; E R Samuels; R W Langley; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2007-07-22       Impact factor: 4.530

5.  Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.

Authors:  P Bitsios; R W Langley; S Tavernor; K Pyykkö; M Scheinin; E Szabadi; C M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  1998-06       Impact factor: 4.335

6.  Infant pupil diameter changes in response to others' positive and negative emotions.

Authors:  Elena Geangu; Petra Hauf; Rishi Bhardwaj; Wolfram Bentz
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

7.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

8.  Modulation of physiological reflexes by pain: role of the locus coeruleus.

Authors:  Elemer Szabadi
Journal:  Front Integr Neurosci       Date:  2012-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.